Heron Therapeutics Q2 net product sales $36.0M; narrows 2024 guidance

HERON THERAPEUTICS, INC. /DE/

2024-Q2 EPS reported -$0.08 revenue$70,694,000

Q2 net product sales $36.0M, up from $31.8M YoY; acute care franchise $6.8M, oncology $29.2M.
ZYNRELEF VAN PDUFA goal date set for September 23, 2024; launch expected before year-end.
2024 guidance narrowed: adjusted operating expenses $107-111M (prev $108-116M), adjusted EBITDA ($10) to $3M (prev ($22) to $3M).
ZYNRELEF included in proposed 2025 NOPAIN Act as a qualifying product effective April 1, 2025.
CrossLink partnership expanding; 561 sales representatives trained to promote ZYNRELEF to orthopedic surgeons.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.